American Century Companies Inc. Decreases Stake in Genmab A/S (NASDAQ:GMAB)

American Century Companies Inc. cut its stake in shares of Genmab A/S (NASDAQ:GMAB) by 2.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 452,195 shares of the company’s stock after selling 12,747 shares during the quarter. American Century Companies Inc. owned about 0.07% of Genmab A/S worth $11,364,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after buying an additional 544 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after purchasing an additional 749 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Genmab A/S during the first quarter valued at $43,000. Barometer Capital Management Inc. purchased a new stake in Genmab A/S in the fourth quarter valued at $121,000. Finally, Headlands Technologies LLC grew its position in Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $25.53 on Monday. The firm has a market capitalization of $16.88 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99. The business’s 50 day moving average price is $27.27 and its 200-day moving average price is $27.98. Genmab A/S has a 1 year low of $24.53 and a 1 year high of $37.00.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. On average, sell-side analysts expect that Genmab A/S will post 1.27 earnings per share for the current year.

Wall Street Analyst Weigh In

GMAB has been the subject of several analyst reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. Truist Financial decreased their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Friday. Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Hold” and a consensus target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.